Pipeline Insight: Epilepsy - Pipeline drugs struggle to outshine their marketed predecessors

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-10-26

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Slow generic uptake, reformulations, follow-on products and new market entrants will ensure steady long-term growth of the epilepsy market despite several high profile patent expiries. UCB has emerged as the number one epilepsy company, and is set to strengthen their epilepsy pipeline if the proposed acquisition of Schwarz is confirmed.


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in epilepsy
  • Overview of drugs in pre-registration, Phase III, II and I; with analysis of key companies involved in the market
  • Detailed profiles of key compounds in development for use in epilepsy, with forecasts of drug revenues to 2015
  • Discussion of UCB, Eisai, and GSK's strategies and insight from key industry opinion leaders


    • Report Highlights
    Following on from Keppra's commercial success, UCB is the current epilepsy market leader. UCB's existing relationship with neurologists will bode well for the potent follow-on compounds, brivaracetam and seletracetam.

    UCB's proposed acquisition of Schwarz will further boost its epilepsy pipeline and CNS marketing/sales capabilities. If the acquisition is completed, Datamonitor believes that UCB will continue to develop Schwarz's Phase III pipeline product lacosamide.

    Generic incursion in the epilepsy market is less profound than in other CNS sectors. Nevertheless, lifecycle management strategies will be necessary to maintain market share following patent expiries. For example, development of sustained release/extended release formulations such as GSK's Lamictal XR can slow generic incursion.


    Reasons to Purchase

  • Understand unmet needs in the epilepsy market based on key opinion leader comments
  • Benchmark key late-stage epilepsy compounds against current market leaders
  • Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: epilepsy epileptic anticonvulsant epilepsy market uk drugs dpvpa pipeline lacosamide clinical drug xr

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.